Top-News
Werbung
Attraktive Knock-Outs auf AbbVie Inc
Typ Hebel Bid / Ask WKN
Call
5,1 3,79 € / 3,81 €
SX4AJ9
Typ Hebel Bid / Ask WKN
Put
5,0 3,89 € / 3,91 €
SW7V1J
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf AbbVie Inc

AbbVie Aktie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
226,79 $
-1,92 $
-0,84%
194,81 € 20:55:16 Uhr
Depot/Watchlist
Marktkapitalisierung *
353,90 Mrd. €
Streubesitz
25,26%
KGV
73,73
Dividende
1,64 $
Dividendenrendite
0,72%
neu: Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 9,34: VG75H6
Werbung

AbbVie News

02.09.25 - PR Newswire
Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers
Health Canada Approves ELAHERE® for Certain Types of Platinum-​Resistant Ovarian Cancers Canada NewsWire
02.09.25 - PR Newswire
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference PR Newswire
25.08.25 - PR Newswire
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline PR Newswire
21.08.25 - PR Newswire
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata PR Newswire
19.08.25 - PR Newswire
AbbVie Completes Acquisition of Capstan Therapeutics
AbbVie Completes Acquisition of Capstan Therapeutics PR Newswire
19.08.25 - PR Newswire
SkinMedica® Unveils Its Newest Hydration Hero
SkinMedica® Unveils Its Newest Hydration Hero PR Newswire
12.08.25 - PR Newswire
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. PR Newswire
06.08.25 - PR Newswire
Get Ready, JUVÉDERM® Day is Calling!
Get Ready, JUVÉDERM® Day is Calling! PR Newswire
05.08.25 - PR Newswire
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency PR Newswire
31.07.25 - wallstreetONLINE Redaktion
Prognose angehoben: Dieser Dividendenstar lässt Anleger am Donnerstag jubeln
Ein Earnings-​Bericht ganz nach dem Geschmack der Anleger: US-​Pharmakonzern Abbvie hat die Erwartungen der Wall Street klar geschlagen und gleichzeitig seine ...
31.07.25 - PR Newswire
AbbVie Reports Second-Quarter 2025 Financial Results
AbbVie Reports Second-​Quarter 2025 Financial Results PR Newswire
31.07.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Blick: Amazon.com, Mastercard, Apple, AbbVie, BMW, Rolls-Royce, Ferrari
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
30.07.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata PR Newswire
29.07.25 - PR Newswire
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic ...
22.07.25 - PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project PR Newswire
10.07.25 - PR Newswire
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-​in-Class CD38×BCMA×CD3 Trispecific Antibody PR Newswire
10.07.25 - PR Newswire
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-​in-Class CD38×BCMA×CD3 Trispecific Antibody PR Newswire
30.06.25 - PR Newswire
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology PR Newswire
30.06.25 - PR Newswire
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance ...
30.06.25 - PR Newswire
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
AbbVie to Host Second-​Quarter 2025 Earnings Conference Call PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »